AFP and hepatocellular carcinoma: Moreover, Pereira et al.' study confirmed that sorafenib could also induce the movement of lymphocytes to HCC tissues and reverse the immunosuppression of HCC [23], while Meizhen et al.' study showed that this drug could downregulate AFP expression and relieve immunosuppression in hepatitis B patients [24].